株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨粗鬆症治療薬の世界市場:2015年〜2019年

Global Osteoporosis Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 295852
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
骨粗鬆症治療薬の世界市場:2015年〜2019年 Global Osteoporosis Drugs Market 2015-2019
出版日: 2015年05月06日 ページ情報: 英文 84 Pages
概要

世界の骨粗鬆症治療薬市場は、2014年から2019年の間、4.14%のCAGRで拡大することが見込まれています。この成長の主な要因のひとつとして、世界的に人口の高齢化が進んでいることが挙げられます。

当レポートでは、世界における骨粗鬆症治療薬市場の現状の分析と将来予測、成長要因や課題、主要ベンダーの情報などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾患の概要

  • 骨粗鬆症とは
  • 疫学と人口統計
  • リスク因子
  • 症状
  • 診断
  • 治療

第7章 骨粗鬆症の治療における主な発展

第8章 市場情勢

  • 市場概要
    • 市場規模と予測
  • 米国市場
    • 市場規模と予測
  • 欧州市場
    • 市場規模と予測
  • ファイブフォース分析

第9章 骨粗鬆症治療薬の世界市場:薬効分類別

  • 骨粗鬆症治療薬の世界市場:薬効分類別の予測
  • 骨吸収抑制治療
  • タンパク同化治療 (アナボリック治療)

第10章 骨粗鬆症治療薬の世界市場:治療ライン別

第11章 パイプライン評価

第12章 骨粗鬆症治療薬の世界市場:地域別

  • 骨粗鬆症治療薬の世界市場:地域別の予測
  • 南北アメリカ
    • 市場規模と予測
  • 欧州・中東・アフリカ地域
    • 市場規模と予測
  • アジア太平洋地域
    • 市場規模と予測

第13章 購入基準

第14章 市場成長因子

第15章 成長因子とその影響

第16章 市場の課題

第17章 成長因子と課題の影響

第18章 市場動向

第19章 動向とその影響

第20章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
    • ベンダーランキング
    • 主要治療薬の評価
    • Amgen
    • Eli Lilly
    • Merck
    • Novartis
  • その他の有力ベンダー

第21章 主要ベンダーの分析

  • Amgen
  • Eli Lilly
  • Merck & Co. Inc.
  • Novartis AG

第22章 関連レポート

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR5759

About osteoporosis

Osteoporosis, or porous bone, is a disease characterized by low bone density and structural deterioration of bone tissue, leading to fragile bones. As bones becomes fragile, risk of fracture increases. Osteoporosis primarily affects women, but can also affect men. In women, bone loss occurs rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement is too slow. Risk factors for osteoporosis include gender, age, low body weight, ethnicity, and family history. Some of the risk factors that can be manipulated include sex hormones, medication use, intake of calcium and vitamins, alcohol intake, and smoking.

Technavio's analysts forecast the global osteoporosis drugs market to grow at a CAGR of 4.14 percent over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global osteoporosis drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs, including products with approved labeling and generic versions.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global osteoporosis drugs market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, clinical stage pipeline molecules developed for the treatment of osteoporosis are discussed.

Technavio's report, Global Osteoporosis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC; it also covers the global osteoporosis drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

Other prominent vendors

  • Abiogen Pharma
  • Deltanoid Pharmaceuticals
  • F. Hoffmann La Roche
  • GlaxoSmithKline
  • IMMD
  • Ligand Pharmaceuticals
  • NPS Pharma
  • Pantarhei Bioscience
  • Pfizer
  • PhytoHealth
  • Radius Health
  • UPSHER-SMITH LABORATORIES
  • Zosano Pharma

Market driver

  • Increase in aging population
  • For a full, detailed list, view our report

Market challenge

  • Multiple expiries of patents
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness about bone health
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding Osteoporosis
  • 06.2. Epidemiology and Demography
  • 06.3. Risk Factors
  • 06.4. Symptoms
  • 06.5. Diagnosis
  • 06.6. Treatment

07. Key Development in Osteoporosis Therapy

08. Market Landscape

  • 08.1. Market Overview
    • 08.1.1. Market Size and Forecast
  • 08.2. Osteoporosis Drugs Market in US
    • 08.2.1. Market Size and Forecast
  • 08.3. Osteoporosis Drugs Market in Europe
    • 08.3.1. Market Size and Forecast
  • 08.4. Five Forces Analysis

09. Market Segmentation by Therapeutic Class

  • 09.1. Global Osteoporosis Drugs Market by Therapeutic Class 2014-2019
  • 09.2. Antiresorptive Medications
  • 09.3. Anabolic Medications

10. Market Segmentation by Line of Therapy

  • 10.1. Global Osteoporosis Drugs Market by Line of Therapy

11. Pipeline Assessment

  • 11.1. Key Information about Pipeline Candidates

12. Geographical Segmentation

  • 12.1. Global Osteoporosis Drugs Market by Geographical Segmentation 2014-2019
  • 12.2. Osteoporosis Drugs Market in Americas
    • 12.2.1. Market Size and Forecast
  • 12.3. Osteoporosis Drugs Market in EMEA
    • 12.3.1. Market Size and Forecast
  • 12.4. Osteoporosis Drugs Market in APAC
    • 12.4.1. Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
    • 20.1.3. Vendor Ranking 2014
    • 20.1.4. Competitive Assessment of Major Drugs
    • 20.1.5. Amgen
    • 20.1.6. Eli Lilly
    • 20.1.7. Merck
    • 20.1.8. Novartis
  • 20.2. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Amgen
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Product Portfolio by Revenue 2013
    • 21.1.5. Business Segmentation by Revenue 2012 and 2013
    • 21.1.6. Geographical Segmentation by Revenue 2013
    • 21.1.7. Business Strategy
    • 21.1.8. Recent Developments
    • 21.1.9. SWOT Analysis
  • 21.2. Eli Lilly
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation by Revenue
    • 21.2.4. Sales by Geography
    • 21.2.5. Business Strategy
    • 21.2.6. Key Information
    • 21.2.7. SWOT Analysis
  • 21.3. Merck & Co. Inc.
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2013
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Business Strategy
    • 21.3.7. Key Developments
    • 21.3.8. SWOT Analysis
  • 21.4. Novartis AG
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis

22. Other Reports in this Series

List Of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Interpretation of BMD Results
  • Exhibit 3: Global Osteoporosis Drugs Market 2014-2019 ($ billion)
  • Exhibit 4: Osteoporosis Drugs Market in US 2014-2019 ($ billion)
  • Exhibit 5: Osteoporosis Drugs Market in Europe 2014-2019 ($ billion)
  • Exhibit 6: Segmentation of Global Osteoporosis Drugs Market by Geography 2014
  • Exhibit 7: Segmentation of Global Osteoporosis Drugs Market by Geography 2019
  • Exhibit 8: Osteoporosis Drugs Market in Americas 2014-2019 ($ billion)
  • Exhibit 9: Osteoporosis Drugs Market in EMEA 2014-2019 ($ billion)
  • Exhibit 10: Osteoporosis Drugs Market in APAC 2014-2019 ($ billion)
  • Exhibit 11: Segmentation of Global Osteoporosis Drugs Market by Geography 2014-2019
  • Exhibit 12: Revenue Comparison of Top Osteoporosis Drugs for First Three Quarters 2014 ($ million)
  • Exhibit 13: YoY Growth Rate and Global Revenue of Prolia 2010-2013 ($ million)
  • Exhibit 14: Revenue of Prolia by Country/Region 2010-2013 ($ million)
  • Exhibit 15: YoY Growth Rate and Global Revenue of Evista 2010-2013 ($ million)
  • Exhibit 16: Revenue of Evista by Country/Region 2010-2013 ($ million)
  • Exhibit 17: YoY Growth Rate and Global Revenue of Forteo 2010-2013 ($ million)
  • Exhibit 18: Revenue of Forteo by Country/Region 2010-2013 ($ million)
  • Exhibit 19: YoY Growth Rate and Global Revenue of Fosamax 2011-2014 ($ million)
  • Exhibit 20: YoY Growth Rate and Global Revenue of Reclast/Aclasta 2010-2013 ($ million
  • Exhibit 21: Revenue of Reclast/Aclasta by Country/Region 2010-2012 ($ million)
  • Exhibit 22: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 23: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 24: Amgen: Business Segmentation by Revenue 2012 and 2013 ($ billion)
  • Exhibit 25: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 26: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 27: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 28: Eli Lilly: Sales by Geography 2013
  • Exhibit 29: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 30: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 ($ billion)
  • Exhibit 31: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 32: Novartis AG: Business Segmentation
  • Exhibit 33: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 34: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
  • Exhibit 35: Novartis AG: Revenue by Geographical Segmentation 2013
Back to Top